{
    "name": "altretamine",
    "comment": "Discontinued",
    "other_names": [
        "Hexalen"
    ],
    "classes": [
        "Antineoplastics",
        "Alkylating"
    ],
    "source": "https://reference.medscape.com/drug/hexalen-altretamine-342191",
    "pregnancy": {
        "common": [
            "Pregnancy Category: D",
            "Lactation: excretion in milk unknown/not recommended"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: excretion in milk unknown/not recommended"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Administer under the supervision of an experienced cancer chemotherapy physician"
            ],
            "specific": [
                {
                    "type": "Bone marrow suppression",
                    "description": [
                        "Perform peripheral blood counts routinely before and after drug therapy"
                    ]
                },
                {
                    "type": "Neurotoxicity",
                    "description": [
                        "Perform neurologic examinations routinely before and after drug therapy"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Pre-existing severe bone marrow suppression or severe neurologic toxicity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Neurotoxic-perform regular neurologic exams",
                "Previous treatment with other myelosuppressive drugs or pre-existing neurotoxicity",
                "Discontinue indefinitely if neurologic symptoms persist on reduced dose",
                "Risk of orthostatic hypotension with concomitant MAO inhibitors, esp in >60 years",
                "Avoid pregnancy"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine quadrivalent, adjuvanted",
            "description": {
                "common": "altretamine decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, altretamine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "altretamine and isavuconazonium sulfate both decrease  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, altretamine.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, altretamine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Anemia",
            "percent": "33"
        },
        {
            "name": "Nausea",
            "percent": "33"
        },
        {
            "name": "vomiting",
            "percent": "31"
        },
        {
            "name": "Peripheral sensory neuropathy",
            "percent": "31"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "9"
        },
        {
            "name": "Alk phos increased",
            "percent": "5"
        },
        {
            "name": "Leukopenia",
            "percent": "1"
        },
        {
            "name": "Anorexia",
            "percent": "1"
        },
        {
            "name": "Seizures",
            "percent": null
        },
        {
            "name": "Alopecia",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Hepatotoxicity",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        }
    ]
}